论文部分内容阅读
目的探讨2型糖尿病患者在服用他汀类药物进行降脂治疗的过程中血清前蛋白转化酶枯草溶菌素9(PCSK9)水平的变化情况。方法采用随机抽样的方法,分别收集31例临床上需要服用他汀类药物进行降脂治疗的2型糖尿病患者用药前和用药4周后的空腹血标本。对入选者进行病史采集、体格检查以及血清生化指标等的检测。采用双抗夹心ELISA的方法检测患者服药前后血清PCSK9的水平。结果他汀类药物能显著降低2型糖尿病患者血清TC、LDL-C、TG等的水平(P<0.01)。口服他汀类药物治疗后2型糖尿病患者的血清PCSK9水平与治疗前相比明显增加,差异有统计学意义(P<0.01)。结论他汀类药物的使用可以升高2型糖尿病患者血清PCSK9的水平,并在一定程度上影响他汀的降脂效果。
Objective To investigate the changes of serum preprotein subtilisin 9 (PCSK9) levels in type 2 diabetic patients treated with statins for lipid-lowering therapy. Methods A total of 31 fasting blood samples were collected from patients with type 2 diabetes mellitus who underwent lipid-lowering therapy on statins before and after 4 weeks of treatment. Candidates for medical history collection, physical examination and serum biochemical detection. The level of serum PCSK9 in patients before and after treatment was measured by double-antibody sandwich ELISA. Results Statins could significantly reduce the levels of TC, LDL-C and TG in type 2 diabetic patients (P <0.01). Serum PCSK9 levels in patients with type 2 diabetes mellitus after oral statin treatment significantly increased compared with those before treatment, with a significant difference (P <0.01). Conclusion The use of statins can increase the level of serum PCSK9 in patients with type 2 diabetes, and to a certain extent, affect the lipid-lowering effect of statins.